Clinical Trials in Egypt / NCT07109778
Starting soon
Observational
Copper to Zinc Ratio in End Stage Renal Disease Patients Outcome
NCT07109778 · tracked via the Priya Life Science Egypt tracker
Condition(s) studied
ESRD (End Stage Renal Disease)Control Condition
Study summary
The goal of this observational clinical trial is to Study the impact of copper to zinc ratio on the outcome of ESRD patients
Eligibility
Inclusion Criteria:
* ESRD patients including those on maintenance HD
Exclusion Criteria:
* Acute kidney injury or rapidly progressive glomerulonephritis, acute infections or active inflammatory conditions as sepsis and autoimmune diseases, liver cirrhosis (Child-Pugh Class B or C), gastrointestinal disorders as inflammatory bowel disease, malabsorption, history of organ transplantation excluding kidney transplantation who may be included in a separate analysis if sufficient numbers are recruited, receiving total parenteral nutrition, Cu or Zn metabolism disorders as Wilson's disease, vitamin complex supplementation or antioxidants within the past 6 months, recent hospitalization within the past 3 months, recent surgery within 3 months, recent blood transfusion \< 3 months, Pregnancy or lactation, Malignancy.
Primary outcome measure(s)
- To determine whether an elevated serum Cu/Zn ratio is associated with an increased risk of cardiac complications in chronic hemodialysis patients. — 6-8 months
measuring serum Cu/Zn ratio and determining if it is associated with an increased risk of cardiac complications in chronic hemodialysis patients.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Nephrology and urology hospital, Minia unersity hospital, Faculty of medicine, Minia university | Minya | Egypt |
More Minia University trials in Egypt
Other trials for the same condition
Management of Iron Deficiency Anemia in Hemodialysis Patients
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07109778 on ClinicalTrials.gov ↗ ← All trials in Egypt